Europe & UK Asia Pacific & Middle East Canada Blood Cancer 2022 About Conference Scientific Sessions/Tracks Abstract Submission Criteria & Eligibility Market Analysis About Conference Cancerconferences is rejoiced to announce the commencement of “17th World Congress on Blood Cancer” during March 22-23...
Clinicians of the day subsequently reported that although leukemia was rare, its disease course was often very rapid and severe and caused death within weeks or months of diagnosis. These reports led to the first suspicions that leukemia might be a blood cell cancer. In 1853, Thomas Hodgkin ...
It is well known that obesity complicates the course of several diseases. However, it is unknown whether obesity affects the risk of infection among health... K Agerg?Rd,Kaspersen,O Birger,... - 《Epidemiology》 被引量: 28发表: 2015年 Rethinking cancer: Should we control rather than kill...
Quality Assurance, Health CareNo abstractdoi:10.1002/pbc.20017Robert J. ArceciJohn Wiley & Sons, Ltd.Pediatric Blood & CancerArceci RJ. Editorial: Setting the course for "Pediatric Blood & Cancer." Pediatr Blood Cancer 2004;42:207-209....
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations. The analysis of cfDNA is often discussed in the context of the noninvas...
Blood Cancer Journal volume 11, Article number: 41 (2021) Cite this article 106k Accesses 103 Altmetric Metrics details Abstract Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various ...
Monoclonal gammopathies (MG) constitute a spectrum of disorders starting from a monoclonal gammopathy of undetermined significance (MGUS) to active disease requiring therapy such as multiple myeloma. MG are characterized by proliferation of clonal plasma
16 The National Cancer Institutes defines adolescent and young adults (AYA) to be those aged 15–39 years. The NCCN recognizes that AYA may benefit from treatment with pediatric-inspired regimens and thus are considered separately from adults >40 years.36, 37 Both age groups are then stratified...
Walsh-McMonagle D, Green D (1997) Low-molecular-weight heparin in the management of Trousseau’s syndrome. Cancer 80:649–655 PubMedCASGoogle Scholar Superficial Sclerosing Phlebitis Chiedozi LC, Aghahowa JA (1988) Mondor’s disease associated with breast cancer. Surgery 103:438–439 ...
This is why we started TRACERx, a Cancer Research UK funded study to track lung cancer evolution in real time, looking at how genetic changes and diversity within tumors affects the course of disease. We've followed hundreds of patients, from diagnosis through to either disease relapse or cure...